Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays decreased their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Performance

Shares of CLLS stock opened at $1.85 on Wednesday. The firm has a market capitalization of $102.83 million, a price-to-earnings ratio of -1.42 and a beta of 3.08. The stock has a fifty day moving average of $1.85 and a 200 day moving average of $2.01. Cellectis has a 52 week low of $1.41 and a 52 week high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same period in the previous year, the firm posted ($0.31) EPS. As a group, research analysts expect that Cellectis will post -0.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in Cellectis during the 2nd quarter valued at about $29,000. First Affirmative Financial Network purchased a new stake in shares of Cellectis during the third quarter valued at approximately $45,000. Principal Financial Group Inc. increased its position in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC raised its holdings in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares during the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.